OTOBIONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OTOBIONE (OTOBIONE).
OTOBIONE is a combination product containing ciprofloxacin (a fluoroquinolone antibiotic) and fluocinolone acetonide (a corticosteroid). Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial cell death. Fluocinolone acetonide suppresses inflammation by binding to glucocorticoid receptors, inhibiting phospholipase A2, and reducing prostaglandin and leukotriene synthesis.
| Metabolism | Ciprofloxacin is partially metabolized in the liver via CYP1A2 and also undergoes renal excretion; fluocinolone acetonide is metabolized via CYP3A4-mediated hydroxylation and reduction, with subsequent glucuronidation and sulfation. |
| Excretion | Renal: 90% unchanged; biliary: <5% as metabolites; fecal: <2% |
| Half-life | 2.5 hours (prolonged to 12-24 hours in renal impairment, CrCl <30 mL/min) |
| Protein binding | 20% (primarily albumin) |
| Volume of Distribution | 0.3 L/kg (restricted to extracellular fluid; negligible CNS penetration) |
| Bioavailability | Topical otic: <5% systemic absorption (intact tympanic membrane); Oral: not applicable |
| Onset of Action | Topical: 15 minutes (otitis externa); Otic drops: 30-60 minutes for local anti-inflammatory effect |
| Duration of Action | 6-8 hours (topical); therapeutic levels maintained for 12 hours with twice-daily dosing |
| Molecular Weight | 585.6 |
1-2 drops in affected ear(s) twice daily; otic administration only.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | 1-2 drops in affected ear(s) twice daily; otic use only. Safety and efficacy in children <1 year not established. |
| Geriatric use | No specific dose adjustment; use same as adult dosing. Caution in reduced hepatic/renal function if systemic absorption suspected. |
| 1st trimester | Avoid due to potential ototoxicity and nephrotoxicity; aminoglycosides cross placenta and may cause fetal harm. |
| 2nd trimester | Avoid unless essential; monitor drug levels and renal function; risk of fetal ototoxicity present. |
| 3rd trimester | Avoid; increased risk of neonatal ototoxicity and nephrotoxicity if administered near term. |
Clinical note
Comprehensive clinical and safety monograph for OTOBIONE (OTOBIONE).
| Placental transfer | Crosses placenta readily; achieves fetal serum concentrations approximately 50-100% of maternal levels. |
| Breastfeeding | Not recommended during breastfeeding. OTOBIONE may be excreted in breast milk and could cause ototoxicity or nephrotoxicity in the nursing infant. Consult physician for alternative therapy. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to OTOBIONE or other aminoglycosidesPre-existing severe renal impairmentPre-existing hearing lossMyasthenia gravis
| Precautions | For otic use only; not for injection or ophthalmic use, Hypersensitivity reactions including anaphylaxis have been reported with ciprofloxacin, Prolonged use may result in overgrowth of non-susceptible organisms including fungi, If infection persists after a full course of therapy, discontinue use and reevaluate, Corticosteroids may mask signs of infection or cause worsening of existing infections, Avoid use in patients with a history of hypersensitivity to any component, fluoroquinolones, or corticosteroids |
| Food/Dietary | No clinically significant food interactions. No restrictions on food or beverages. |
Loading safety data…
| Lactation Rating |
| L4 (Contraindicated) |
| Teratogenic Risk | FDA Category C. No adequate human studies; animal studies suggest risk. Avoid in first trimester unless benefit outweighs risk. Potential for ototoxicity in fetus if used near term. |
| Fetal Monitoring | Monitor maternal renal function, hearing (audiometry) and vestibular function. Fetal ultrasound for growth restriction if used long-term. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies show no impairment. |
| Clinical Pearls | Ofloxacin otic solution is contraindicated in patients with perforated tympanic membrane due to risk of ototoxicity. Administer at room temperature; warm bottle in hands for 1-2 minutes before instillation to avoid caloric vertigo. For optimal penetration, patient should lie on opposite side for 5 minutes after instillation. Avoid contaminating dropper tip. Do not use for viral or fungal infections. Efficacy maintained in acidic pH of ear canal. |
| Patient Advice | Use exactly as prescribed; do not stop early even if symptoms improve. · Warm the bottle in your hand for 1-2 minutes before use to prevent dizziness. · Lie on your side with affected ear up for 5 minutes after drops to ensure medication penetrates. · Keep the dropper tip clean; do not touch ear or any surface. · Avoid swimming or getting water in the ear while using this medication. · Report any hearing loss, ringing, or severe dizziness to your doctor immediately. |